子宮頚癌の浸潤、転移におけるICAM-1の役割に関する研究

ICAM-1在宫颈癌侵袭转移中的作用研究

• 批准号: 08771342
• 负责人: 奈須 家栄
• 金额: $ 0.64万
• 依托单位: 大分医科大学
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Encouragement of Young Scientists (A)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 无数据
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-08771342/
• 关键词: 子宮頚癌; ICAM-1; 腫瘍マーカー; CD54

子宮頚癌34例(0期9例、I期7例、II期3例、III期5例、IV期3例、再発7例)と正常婦人16例を対象としてELISA法により、血清ICAM-1値を測定した。測定結果は子宮頚癌0期:274±39ng/ml、I期:339±136ng/ml、II期:554±131ng/ml、III期:498±155ng/ml、IV期451±108ng/ml、再発:503±111ng/ml、正常対照294±84ng/mlで、腫瘍の子宮外への進展や再発に伴って、血清ICAM-1値は上昇する傾向が認められた(対照VSII期、p<0.05;対照VSIII期、p<0.05;対照VS再発、p<0.01;0期VSII期、p<0.025;0期VSIII期、p<0.05;0期VS再発、p<0.025;Scheffe's F test)。また、正常子宮頚部組織3例、初発進行癌4例よりtotal RNAを抽出し、RT-PCRによりICAM-1mRNAの発現について検討したところ、子宮頚癌4例中1例と正常子宮頚部3例ではICAM-1 mRNAの発現が確認された。さらに、抗ICAM-1抗体を用いて免疫組織染色を行なうと、血管内皮細胞、炎症細胞および腫瘍細胞が陽性となった。以上より、子宮頚癌においてICAM-1の腫瘍内での産生が増加し、一部が血中へ放出されていることが示唆された。ICAM-1は子宮頚癌の進展のメカニズムの一つとして関与しているものと思われる。

There were 34 cases of cancer (stage 0 (n = 9), stage I (n = 7), stage II (n = 3), stage III (n = 5), stage IV (n = 3), stage IV (n = 7) and normal controls (n = 16). Serum ICAM-1 was measured by ELISA method. The results show that stage 0: 27439 ng/ml, period I: 339 ±136 ng/ml, period II: 554 ±131 ng/ml, period III: 498 ±155 ng/ml, period III: 498 ±155 ng/ml, IV period 451 ±108ng/ml, revisit: 503 ±111 ng/ml, normal photo 294 ±84ng/ml, serum ICAM-1 cycle progression to follow-up cycles (VSII phase, pairltscape 0.05), VSIII phase, pairltscape 0.05 According to VS rebirth, pairltter0.01scheffeters0phase VSII, pamphltter0.025scheffeters0phase VSIII, pamplltpolitics 0.05transfers0phase VS repertoire, pairlttransfer0.025scheffeforth F test). There were 3 cases of malignant tumor, 3 cases of normal child tissue, 4 cases of primary cancer, 4 cases of primary cancer, 3 cases of normal fetal tissue, 4 cases of primary cancer, 4 cases of primary cancer, 4 cases of primary cancer, 3 cases of primary cancer, 4 cases of primary cancer, 3 cases of primary cancer, 4 cases of primary cancer, 3 cases of primary cancer, 4 cases of primary cancer, 4 cases of primary cancer, 3 cases of normal fetal tissue, 4 cases of primary cancer, 4 cases of primary cancer Immunocytochemistry and anti-ICAM-1 antibodies were detected by immuno-histochemical staining. Vascular endothelial cells and inflammatory cells were detected by immunocytochemistry. The above drugs, children, cancer patients, ICAM-1 children, children, ICAM-1 is suffering from cancer progression. The first step is to get rid of each other.

项目成果

奈須家栄: "子宮頚癌におけるICAM-1の発現" 産婦人科の実際. (in press).

Sakae Nasu：“ICAM-1 在宫颈癌中的表达”妇产科实践（正在出版）。